ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Liu, Hu; Cheng, Ying; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Ye, Changsheng; Dong, Fangli; Wu, Shuchao; Zhu, Xiaoyu; Xu, Binghe*华中科技大学; 吉林大学; 南方医科大学; 哈尔滨医科大学; 河北医科大学; 四川大学; 郑州大学; 西安交通大学; 中国医科大学; 中国医学科学院; 中山大学; 重庆大学; 中国医学科学院北京协和医院; 1
BRITISH MEDICAL JOURNAL2023-10-31DOI: 10.1136/bmj-2023-076065
3被引9阅读
引用收藏
分享

摘要

OBJECTIVE To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer. DEsIGN Randomised, double blind, placebo controlled, multicentre, phase 3 trial. sETTING 40 centres in China between 6 May 2019 and 17 January 2022. PARTICIPANTs 590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer. INTERVENTIONs Eligible patients were randomised 1:1 to receive either oral pyrotinib (400 mg once daily) or placebo, both combined with intravenous trastuzumab (8 mg/ kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day cycle. Randomisation was stratified by treatment history of trastuzumab in the (neo)adjuvant setting and hormone receptor status. Patients, investigators, and the sponsor's study team were masked to treatment assignment. MAIN OUTCOME MEAsUREs The primary endpoint was progression-free survival as assessed by the investigator. REsULTs Of the 590 randomised patients, 297 received pyrotinib, trastuzumab, and docetaxel treatment (pyrotinib group), and 293 received placebo, trastuzumab, and docetaxel treatment (placebo group). At data cut-off on 25 May 2022, the median follow-up was 15.5 months. The median progression- free survival according to the investigator was significantly longer in the pyrotinib group than in the placebo group (24.3 (95% confidence interval 19.1 to 33.0) months versus 10.4 (9.3 to 12.3) months; hazard ratio 0.41 (95% confidence interval 0.32 to 0.53); one sided P<0.001). Treatment related adverse events of grade 3 or higher were reported in 267 (90%) of the 297 patients in the pyrotinib group and 224 (76%) of the 293 patients in the placebo group. No treatment related deaths occurred in the pyrotinib group, and one (<1%; diabetic hyperosmolar coma) treatment related death occurred in the placebo group. Survival and toxicities are still under assessment with longer follow-up. CONCLUsIONs Pyrotinib, trastuzumab, and docetaxel showed superiority by significantly improving progression- free survival compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2 positive metastatic breast cancer. The toxicity was manageable. The findings support this dual anti-HER2 regimen as an alternative first line treatment option in this patient population. TRIAL REGIsTRATION ClinicalTrials.gov NCT03863223.

学科与关键词

关键词
PROGRESSION-FREE SURVIVALLAPATINIB PLUS CAPECITABINETYROSINE KINASE INHIBITOROPEN-LABELEND-POINTPERTUZUMABRECEPTORDIARRHEASAFETYMANAGEMENT
相关
加载中…
  • Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
    Zheng, Yabing; Cao, Wen-Ming; Shao, Xiying; Shi, Yanxia; Cai, Li; Chen, Wenyan; Liu, Jian; Shen, Peng; Chen, Yiding; Wang, Xian; Li, Huiping; Li, Man; Chen, Zhanhong*; Wang, Xiaojia*Nature Communications, 2023, 14(1): 8314.
  • Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
    Xu, B.; Yan, M.; Ma, F.; Li, W.; Ouyang, Q.; Tong, Z.; Teng, Y.; Wang, S.; Wang, Y.; Geng, C.; Luo, T.; Zhong, J.; Zhang, Q.; Liu, Q.; Zeng, X.; Sun, T.; Mo, Q.; Dong, F.; Wu, S.; Zhu, X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 11
  • Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
    Xie, Yizhao; Li, Yi; Ting, Luo; Sang, Die; Yuan, Peng; Li, Wei; Li, Huihui; Ge, Rui*; Wang, Biyun*Frontiers in Oncology, 2021, 11: 699333.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
BRITISH MEDICAL JOURNAL
发表日期
2023-10-31
卷期
第 383 卷
页码
e076065
DOI
10.1136/bmj-2023-076065
成果收录
SCIE

作者

  • M

    Ma, Fei (第一作者)

    chinese acad med sci · peking union med coll

  • Y

    Yan, Min

    zhengzhou univ

查看全部 30 位作者收起作者
  • L

    Li, Wei

    jilin univ

  • O

    Ouyang, Quchang

    hunan canc hosp

  • T

    Tong, Zhongsheng

    tianjin med univ canc inst & hosp

  • T

    Teng, Yuee

    1 · china med univ

  • W

    Wang, Yongsheng

  • W

    Wang, Shusen

    sun yat sen univ

  • G

    Geng, Cuizhi

    hebei med univ

  • L

    Luo, Ting

    sichuan univ

  • Z

    Zhong, Jincai

    1 · guangxi med univ

  • Z

    Zhang, Qingyuan

    harbin med univ

  • L

    Liu, Qiang

    sun yat sen univ

  • Z

    Zeng, Xiaohua

    chongqing univ

  • S

    Sun, Tao

    liaoning canc hosp & inst · chongqing univ

  • M

    Mo, Qinguo

    guangxi med univ

  • L

    Liu, Hu

    1 · ustc

  • C

    Cheng, Ying

  • C

    Cheng, Jing

    huazhong univ sci & technol

  • W

    Wang, Xiaojia

    zhejiang canc hosp

  • N

    Nie, Jianyun

  • Y

    Yang, Jin

    1 · xi an jiao tong univ

  • W

    Wu, Xinhong

    hubei canc hosp

  • W

    Wang, Xinshuai

    1 · henan univ

  • L

    Li, Huiping

    peking univ canc hosp & inst

  • Y

    Ye, Changsheng

    southern med univ

  • D

    Dong, Fangli

  • W

    Wu, Shuchao

  • Z

    Zhu, Xiaoyu

  • X

    Xu, Binghe (通讯)

    chinese acad med sci · peking union med coll

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417